Innovating Works

SERENDIP GMBH

Desconocido
CARES: Human ECM based platform for anti cancer drug testing CARES CAncer dRug tESting SERENDIP GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2022-SE-01 With 2 million cancer-related deaths and an annual cost of €100 billion, cancer constitutes a major European challenge. Cancer treatments ha...
2023-07-03 - 2027-10-31 | Financiado
HEPINIB: Heparanase inhibition as a multifunctional targeting approach in cancer SERENDIP GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2021-SE-01 Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the dise...
2022-10-28 - 2026-12-31 | Financiado
MOMENDO: Molecular Mechanisms of Endometriosis SERENDIP GMBH participó en un H2020: H2020-MSCA-RISE-2015 Endometriosis (the presence of endometrial-like tissue or ‘lesions’ outside the uterus) is a chronic inflammatory disease affecting 6-10% of...
2015-11-04 - 2019-12-31 | Financiado
GLYCANC: Matrix glycans as multifunctional pathogenesis factors and therapeutic targets in cancer SERENDIP GMBH participó en un H2020: H2020-MSCA-RISE-2014 Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the dise...
2014-11-25 - 2019-06-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.